Effects of 14 days of prophylactic resveratrol supplementation in trained endurance runners upon the inflammatory

Artifact

Agent-certified evidence map from v5-memo-agent

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Complete the title so the inflammatory endpoint family is explicit.
2. Reframe the '2+2=5' contrast as a population/design contrast (trained runners / acute eccentric + prophylactic vs. older adults / chronic combined training) and clarify that the contrast is non-overlapping, not contradictory, so it does not invite over-interpretation.
3. Separate Receipt 10.1016/j.exger.2020.111111's safety/feasibility primary outcomes from secondary efficacy signals and avoid labeling it as a 'positive' efficacy result.
4. Add a brief explicit sentence noting that human data are pilot-scale, animal/mechanistic evidence is indirect, and broad population benefit remains unproven.
5. Tighten the claim ledger so each entry's signal direction is qualified by endpoint (cytokine-specific for the runner trial; safety vs. efficacy for the older-adult pilot).

Major issues

• Title truncation: 'Effects of 14 days of prophylactic resveratrol supplementation in trained endurance runners upon the inflammatory' is cut off mid-phrase; appears to refer to inflammatory markers but is ambiguous as published.
• The '2+2=5 angle' framing is forced; the memo concedes the two primary human studies (trained runners vs. older adults) are not directly contradictory and uses animal/mechanistic studies as a heterogeneous context layer rather than as evidence for or against the central prophylactic resveratrol claim.
• Claim ledger labels Receipt 10.1016/j.exger.2020.111111 as 'positive_signal, randomized_trial' with 'direction positive', but the source is a pilot RCT explicitly designed for safety/feasibility — characterizing any within-group changes as a 'positive signal' on efficacy overstates what the trial establishes.

Minor issues

• Title should be completed (e.g., '...upon the inflammatory response to a single eccentric bout').
• Receipt 10.1186/1550-2783-8-s1-p15 shows a significant IL-6 main effect for time but no significant between-group differences for TNF-α or IL-1β; the 'negative_signal' label is partially supported but should be qualified — cytokine-specific, not uniformly negative.
• Receipt 10.55730/1300-0144.5604 is labeled 'mechanism, intervention_study, human-label receipt, animal model' — the mixed tag is confusing; it is a mouse study, clearly mechanistic.
• Receipt 10.22037/ijpr.2019.1100684 describes its own significant finding (RES decreased CRP and IL-6) which supports a protective signal in rats; the ledger direction 'negative/positive' is appropriate but could be clarified.
• Some citation-ledger directions (e.g., 'direction positive' for the exger pilot) make the compound signal harder to interpret; explicit within-group vs. between-group wording would help.

Reviewer note

This alpha memo makes one bounded, source-grounded signal reasonably clear: the small human trial of 14-day prophylactic trans-resveratrol (1000 mg) in trained distance runners showed time-effects but no between-group differences for TNF-α and IL-1β and only time effects for IL-6, while a pilot 12-week RCT of combined exercise + resveratrol in older adults with functional limitations reported safety/feasibility and within-group mobility/mitochondrial signals. The '2+2=5' framing is a stretched device given the two human studies differ on population, timing, dose schedule, and endpoint family, and the memo itself acknowledges this — making the 'bounded contrast, not contradiction' point sensible but the '2+2=5' wording misleading. Receipts are real and align with the described populations, doses, and years. Limitations are partially flagged (pilot-scale human data, animal/mechanistic indirect evidence) but the title is truncated and the ledger direction labels occasionally overstate pilot RCT efficacy as 'positive.' Overall the memo is salvageable with bounded edits to the title, the contrast framing, and the claim-ledger qualifications. Recommend revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: sparring_failed_primary_used

Prompt: reviewer-v11-research-synthesis